Oscar Tahuahua, Medical Oncology Fellow at National Cancer Institute(Mexico), shared an article by Shunsuke Nakatani, et al. on X:
“Systematic Review and Meta-analysis in HER2+ Breast Cancer Patients.
HER2 loss post NACT (21.4%) linked to higher recurrence (HR 1.85, p=0.0005) & worse OS (HR 2.37, p=0.0065).
Mechanisms: tumor heterogeneity, acquired resistance & clonal selection. Should HER2 reassessment guide tx?”
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2 positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis.
Authors: Shunsuke Nakatani, et al.
